Burden of hereditary transthyretin amyloidosis on quality of life.

"Conflicts of Interest: M.P. is an employee of and owns stock in Akcea Therapeutics. S.G. was an employee of and owned stock in Akcea Therapeutics when this research was conducted. A.Y., A.L., A.S.K., and M.K.W. are employees of Optum, which received payment from Akcea Therapeutics to conduct these analyses and develop this article. M.A.G. has received consulting fees from Alnylam, Ionis, and Prothena. N.D. has participated on the cardiology advisory boards for Ionis, Akcea Therapeutics, and Pfizer and has been on the speakers’ bureau for Akcea Therapeutics and Pfizer. L.O. has received speaking and consulting fees from Akcea Therapeutics, Pfizer, and Alnylam. E.J.A. has received consulting fees from Akcea Therapeutics. The remaining authors have no conflicts of interest to disclose. Akcea Therapeutics developed and is marketing a drug, inotersen (Tegsedi) for treating hereditary transthyretin (hATTR) amyloidosis using antisense oligonucleotide technology."

"Funding: Akcea Therapeutics."